Co-Diagnostics Vector Smart® Division Expands Footprint to 21 States
Co-Diagnostics (Nasdaq: CODX) reported that its Vector Smart mosquito abatement district customer base now spans 21 states, with four new full laboratory installs in June 2026.
Rhea-AI Summary
Co-Diagnostics (Nasdaq: CODX) reported that its Vector Smart mosquito abatement district customer base now spans 21 states, with four new full laboratory installs in June 2026. The expansion aligns with a Co-Dx webinar for prospective MAD customers during National Mosquito Control Awareness Week.
Vector Smart multiplex PCR tests target West Nile, multiple encephalitis viruses, Zika, dengue and chikungunya, supporting decentralized, in-house PCR testing and faster vector-borne disease surveillance for communities.
Positive
- Vector Smart footprint expanded to mosquito abatement districts in 21 U.S. states
- Four new Vector Smart labs installed for MAD customers in June 2026
- Multiplex PCR panels cover multiple mosquito-borne diseases, including West Nile and Zika
- Strategy emphasizes decentralized, in-house PCR testing at the point of need
Negative
- None.
Details
News Market Reaction – CODX
In the Jun 25 session, CODX declined 14.57%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Vector Smart footprint
- 21 states
- Mosquito abatement district customers using Vector Smart products and services
- New lab installs
- 4 full laboratory installs
- Added for Vector Smart customers in June 2026
- Vector-borne deaths
- more than 700,000 deaths annually
- Global toll from mosquito-carried vector-borne diseases per WHO
- S-3 resale registration
- 4,942,341 shares
- Shares registered for resale by selling stockholders on S-3
- Potential warrant proceeds
- $5.18 million
- Maximum cash proceeds if registered warrants are exercised
- Shares outstanding
- 3,685,314 shares
- Common shares outstanding as of May 27, 2026
- Schedule 13G ownership
- 236,359 shares (6.4%)
- Jane Street Group and subsidiaries’ reported CODX common stock position
- Price vs 52-week high
- -92.35%
- CODX price relative to 52-week high before this news
Historical Context
-
Hosted Saudi JV for unveiling of future automated PCR manufacturing line.
-
Exclusive Mexico distribution deal extending partner relationship for PCR platform.
-
Progress on Ebola PCR tests and Co-Dx PCR Pro point-of-care capabilities.
-
Advanced Ebola assay strategy targeting Bundibugyo outbreak with JV CoSara.
-
$3.0M private placement with common and pre-funded warrant securities.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
vector-borne diseases medical
multiplex pcr tests technical
pcr tests technical
decentralized pcr technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Expansion coincides with Co-Dx webinar for prospective mosquito abatement district customers in honor of National Mosquito Control Awareness Week
"Our Vector Smart division continues to gain traction, and we believe the pace of new customer additions this month reflects both the strength of our technology and a growing urgency around vector-borne disease surveillance," said Dwight Egan, CEO of Co-Diagnostics. "Co-Diagnostics is a leader in the space to provide PCR tests to mosquito abatement districts for in-house PCR testing, decentralizing mosquito pool testing to allow for more informed operational decisions in communities where MADs operate."
According to the World Health Organization, vector-borne diseases carried by mosquitos cause more than 700,000 deaths annually. In June 2026,
Mr. Egan continued, "Co-Diagnostics believes that decentralizing PCR testing to the point of need enables faster, data-driven vector surveillance and better coordination between public health agencies. Because disease-carrying mosquitoes move across jurisdictional boundaries, timely collection and sharing of surveillance data can be critical to protecting communities. We are committed to remaining at the forefront of innovation for decentralized PCR, for vector control applications as well as infectious disease testing worldwide."
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will," "seeks," "anticipates," and similar expressions, or the negative of these terms. Forward-looking statements in this press release include, but are not limited to; (i) statements regarding in-house mosquito pool testing allowing for quicker reaction times and improved health outcomes; and (ii) decentralizing PCR testing to the point of need enabling faster, data-driven vector surveillance while supporting collaboration between public health agencies. Such statements are subject to a number of risks and uncertainties, including, without limitation risks related to the performance, reliability, and market acceptance of the Co-Dx Vector Smart tests and other Co-Dx technology; risks associated with dependence on third parties, suppliers, collaborators, and distribution partners; risks related to competition, technological change, and intellectual property protection; and other risks described from time to time in the Company's filings with the Securities and Exchange Commission ("SEC"). Actual results may differ materially from those expressed or implied in these forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. A further description of risks and uncertainties can be found in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2026, and in its other filings with the SEC. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-vector-smart-division-expands-footprint-to-21-states-302810293.html
SOURCE Co-Diagnostics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.